Picture of Sonnet Biotherapeutics Holdings logo

SONN — Sonnet Biotherapeutics Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Sonnet Biotherapeutics Holdings Inc expected to post a loss of $5.52 a share - Earnings Preview

* Sonnet Biotherapeutics Holdings Inc  SONN.OQ   SONN.O  is
expected to show a fall in quarterly revenue when it reports 
results on December 12 (estimated) for the period ending
September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Sonnet Biotherapeutics
Holdings Inc is for a loss of $5.52 per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $240.00​, above​ its last
closing price of $1.98. ​​​

This summary was machine generated December 10 at 21:02 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Sonnet Biotherapeutics Holdings

See all news